ERBB2 and breast cancer: The tumorigenesis process and persistence of HER2+ BC cells are prevented by adverse reactions to IGF2/IGF-1R/IRS1, and anti-IGF-1R combination therapy is resistant to trastuzumab (Wu et al., 2022).